Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Mar;63(3):368-75.
doi: 10.1111/j.1742-1241.2008.01988.x.

The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas

P E Pertel  1 , B I Eisenstein, A S Link, B Donfrid, E J A Biermann, P Bernardo, W J Martone
Affiliations
Free PMC article
Randomized Controlled Trial

The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas

P E Pertel et al. Int J Clin Pract. 2009 Mar.
Free PMC article

Abstract

Background: Results from previous trials suggest that daptomycin may result in faster clinical improvement than penicillinase-resistant penicillins or vancomycin for patients with complicated skin and skin structure infections.

Objective: The objective was to evaluate whether daptomycin treatment of cellulitis or erysipelas would result in faster resolution compared with vancomycin.

Design: The study was a prospective, evaluator-blinded, multi-centre trial. Patients were randomised to receive daptomycin 4 mg/kg once daily or vancomycin according to standard of care for 7-14 days.

Patients: Adults diagnosed with cellulitis or erysipelas requiring hospitalisation and intravenous antibiotic therapy were eligible for enrolment.

Results: The clinical success rates were 94.0% for daptomycin and 90.2% for vancomycin (95% confidence interval for the difference, -6.7%, 14.3%). There were no statistically significant differences between treatment arms in the time to resolution or improvement in any of the predefined clinical end-points. Both daptomycin and vancomycin were well tolerated.

Conclusions: There was no difference in the rate of resolution of cellulitis or erysipelas among patients treated with daptomycin or vancomycin. Daptomycin 4 mg/kg once daily appeared to be effective and safe for treating cellulitis or erysipelas.

Trial registration: ClinicalTrials.gov NCT00295178.

PubMed Disclaimer

References

    1. Pfaller MA, Sader HS, Jones RN. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002–2005) Diagn Microbiol Infect Dis. 2007;57:459–65. - PubMed
    1. Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002–2004) Clin Microbiol Infect. 2006;12:844–52. - PubMed
    1. Castanheira M, Jones RN, Sader HS. Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006) Diagn Microbiol Infect Dis. 2008;61:235–9. - PubMed
    1. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and-resistant strains. Antimicrob Agents Chemother. 2000;44:1062–6. - PMC - PubMed
    1. Diederen BM, van Duijn I, Willemse P, Kluytmans JA. In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains. Antimicrob Agents Chemother. 2006;50:3189–91. - PMC - PubMed

Publication types

Associated data